Description de l'entreprise
RELIEF THERAPEUTICS Holding AG was formed in June 2016 following the merger of Relief Therapeutics SA and THERAMetrics Holding AG. RELIEF THERAPEUTICS Holding AG is a clinical stage biotechnology company with a portfolio of drug candidates derived from natural human origins. Its two most promising drug candidates are Aviptadil for the treatment of sarcoidosis (already in Phase III) and low dose interleukin-6 (Atexakin Alfa) for the treatment of peripheral diabetic neuropathy (already in Phase II). Aviptadil development in sarcoidosis focuses the drug on an orphan disease market, in which European regulators have indicated that a single pivotal Phase III trial would be sufficient to support approval. Atexakin Alfa is in Phase II and has been the subject of multiple clinical trials. Based on its unique mechanism of action, Atexakin Alfa could become the first regenerative therapeutic for peripheral neuropathy.
Conseil d'administration & Conseil de surveillance
| PDG |
| Jack Weinstein |
| Conseil d'administration |
| Jeremy Meinen, Marco Marotta, Nermeen Varawalla, Paolo Galfetti |
| Conseil de surveillance |
| Dr. Raghuram Selvaraju, Tom Plitz, Paolo Galfetti, Patrice P. Jean, Michelle Lock |
Données de l'entreprise
| Nom: |
RELIEF THERAPEUTICS Holding AG |
| Adresse: |
Avenue de Sécheron 15,CH-1202 Genève |
| Téléphone: |
+41-44-7235959 |
| Fax: |
- |
| Courriel: |
contact@relieftherapeutics.com
|
| Internet: |
www.relieftherapeutics.com/ |
| Industrie: |
Biotechnology |
| Secteur: |
Biotechnology |
| Sous-secteur: |
Biotechnology |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
44.53% |
| IPO date: |
- |
